Media coverage about Transgenomic (NASDAQ:PRPO) has been trending somewhat positive on Saturday, according to Accern Sentiment Analysis. The research firm scores the sentiment of press coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Transgenomic earned a daily sentiment score of 0.08 on Accern’s scale. Accern also gave news articles about the biotechnology company an impact score of 45.2527209276521 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.

Transgenomic (NASDAQ PRPO) traded down 3.07% during trading on Friday, reaching $2.21. The company had a trading volume of 65,541 shares. Transgenomic has a 52 week low of $2.20 and a 52 week high of $47.70. The firm’s market capitalization is $1.98 million. The stock has a 50 day moving average price of $6.25 and a 200 day moving average price of $7.14.

Separately, ValuEngine downgraded Transgenomic from a “sell” rating to a “strong sell” rating in a research report on Tuesday, August 1st.

COPYRIGHT VIOLATION NOTICE: This report was published by Watch List News and is the sole property of of Watch List News. If you are accessing this report on another site, it was copied illegally and reposted in violation of United States & international copyright law. The correct version of this report can be viewed at

Transgenomic Company Profile

Precipio, Inc, formerly Transgenomic, Inc, is a biotechnology company. The Company is engaged in advancing personalized medicine for the detection and treatment of cancer, and inherited diseases through its molecular technologies and clinical and research services. The Company operates through its Laboratory Services segment.

Receive News & Ratings for Transgenomic Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Transgenomic Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.